Skip to main content

Mycobacterium Avium-Intracellulare Infection

1
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
1
clarithromycinPhase 2
Amgen
AmgenTHOUSAND OAKS, CA
1 program
trifluridineN/A3 trials
Active Trials
NCT00002037Completed15
NCT06680622Active Not Recruiting126Est. Mar 2028
NCT05198934Completed160Est. Apr 2026
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
ClarithromycinPHASE_21 trial
Active Trials
NCT00000644Completed100

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
Amgentrifluridine
Amgentrifluridine

Clinical Trials (4)

Total enrollment: 401 patients across 4 trials

NCT05198934Amgentrifluridine

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

Start: Apr 2022Est. completion: Apr 2026160 patients
Phase 3Completed

A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS

100 patients
Phase 2Completed
NCT06680622Amgentrifluridine

Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

Start: Mar 2025Est. completion: Mar 2028126 patients
Phase 2Active Not Recruiting
NCT00002037Amgentrifluridine

Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

15 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.